Roles of FoxM1-driven basal β-cell proliferation in maintenance of β-cell mass and glucose tolerance during adulthood.
Advancing age
β-Cell mass maintenance
β-Cell proliferation
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
12
05
2022
received:
17
03
2022
accepted:
26
05
2022
pubmed:
29
5
2022
medline:
7
10
2022
entrez:
28
5
2022
Statut:
ppublish
Résumé
Whether basal β-cell proliferation during adulthood is involved in maintaining sufficient β-cell mass, and if so, the molecular mechanism(s) underlying basal β-cell proliferation remain unclear. FoxM1 is a critical transcription factor which is known to play roles in 'adaptive' β-cell proliferation, which facilitates rapid increases in β-cell mass in response to increased insulin demands. Therefore, herein we focused on the roles of β-cell FoxM1 in 'basal' β-cell proliferation under normal conditions and in the maintenance of sufficient β-cell mass as well as glucose homeostasis during adulthood. FoxM1 deficiency was induced specifically in β-cells of 8-week-old mice, followed by analyzing its short- (2 weeks) and long- (10 months) term effects on β-cell proliferation, β-cell mass, and glucose tolerance. FoxM1 deficiency suppressed β-cell proliferation at both ages, indicating critical roles of FoxM1 in basal β-cell proliferation throughout adulthood. While short-term FoxM1 deficiency affected neither β-cell mass nor glucose tolerance, long-term FoxM1 deficiency suppressed β-cell mass increases with impaired insulin secretion, thereby worsening glucose tolerance. In contrast, the insulin secretory function was not impaired in islets isolated from mice subjected to long-term β-cell FoxM1 deficiency. Therefore, β-cell mass reduction is the primary cause of impaired insulin secretion and deterioration of glucose tolerance due to long-term β-cell FoxM1 deficiency. Basal low-level proliferation of β-cells during adulthood is important for maintaining sufficient β-cell mass and good glucose tolerance and β-cell FoxM1 underlies this mechanism. Preserving β-cell FoxM1 activity may prevent the impairment of glucose tolerance with advancing age.
Identifiants
pubmed: 35633298
doi: 10.1111/jdi.13846
pmc: PMC9533047
doi:
Substances chimiques
Forkhead Box Protein M1
0
Insulin
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1666-1676Subventions
Organisme : Japan Science and Technology Agency
ID : [Moonshot R&D] [Grant Number JPMJPS2023]
Organisme : Japan Agency for Medical Research and Development
ID : 21gm6210002h0004 (AMED-PRIME)
Organisme : Japan Agency for Medical Research and Development
ID : JP21gm5010002h0005
Organisme : Japan Society for the Promotion of Science
ID : 22H03124
Organisme : Japan Society for the Promotion of Science
ID : 20H05694
Organisme : Japan Society for the Promotion of Science
ID : 20K17525
Informations de copyright
© 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Science. 2008 Nov 21;322(5905):1250-4
pubmed: 19023081
J Gerontol. 1993 Mar;48(2):B74-8
pubmed: 8473691
Liver. 2002 Oct;22(5):419-25
pubmed: 12390477
PLoS One. 2010 Oct 22;5(10):e13533
pubmed: 21063464
Mol Cell Biol. 1997 Mar;17(3):1626-41
pubmed: 9032290
Diabetes. 2015 Nov;64(11):3829-38
pubmed: 26251404
Diabetes. 2010 Jan;59(1):143-52
pubmed: 19833884
Diabetes. 2011 Feb;60(2):537-47
pubmed: 21270264
Genes Dev. 2017 Feb 1;31(3):228-240
pubmed: 28270515
Diabetes. 2005 Sep;54(9):2557-67
pubmed: 16123343
Nat Commun. 2017 Dec 5;8(1):1930
pubmed: 29208957
Adv Cancer Res. 2013;118:97-398
pubmed: 23768511
Gastroenterology. 2006 Apr;130(4):1283-300
pubmed: 16618419
Nat Cell Biol. 2005 Feb;7(2):126-36
pubmed: 15654331
Science. 1997 Apr 4;276(5309):60-6
pubmed: 9082986
Mol Metab. 2017 Jul 08;6(9):943-957
pubmed: 28951820
Genesis. 2000 Feb;26(2):139-42
pubmed: 10686610
Diabetes. 2008 Jun;57(6):1584-94
pubmed: 18334605
Diabetes. 2008 Nov;57(11):3069-77
pubmed: 18728229
Diabetes. 2009 Jun;58(6):1365-72
pubmed: 19265026
J Vet Med Sci. 2009 Jun;71(6):745-52
pubmed: 19578282
Biochem Biophys Res Commun. 2005 Jan 14;326(2):402-9
pubmed: 15582592
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2334-9
pubmed: 16461897
J Biol Chem. 2002 Nov 15;277(46):44310-6
pubmed: 12221098
Mol Endocrinol. 2006 Aug;20(8):1853-66
pubmed: 16556734
Endocr J. 2008 May;55(2):235-52
pubmed: 17938503
Sci Rep. 2017 Oct 3;7(1):12643
pubmed: 28974717
J Mol Endocrinol. 2007 Feb;38(1-2):193-206
pubmed: 17293440
Nat Commun. 2018 Dec 13;9(1):5300
pubmed: 30546054
J Clin Invest. 2007 Sep;117(9):2553-61
pubmed: 17786244
Immunobiology. 1997 Dec;198(1-3):157-61
pubmed: 9442387
J Clin Endocrinol Metab. 2010 Oct;95(10):E234-9
pubmed: 20660050
J Clin Invest. 2013 Mar;123(3):990-5
pubmed: 23454762
Science. 1997 Oct 17;278(5337):419-24
pubmed: 9334293
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16881-6
pubmed: 12482952
Nat Med. 2010 Jul;16(7):804-8
pubmed: 20581837
Diabetologia. 2010 Feb;53(2):321-30
pubmed: 19855953
J Biol Chem. 2003 Sep 26;278(39):37888-94
pubmed: 12867420
Nature. 2004 May 6;429(6987):41-6
pubmed: 15129273
Diabetes. 2009 Jun;58(6):1312-20
pubmed: 19228811
J Clin Invest. 2004 Oct;114(7):963-8
pubmed: 15467835
Hepatology. 2003 Dec;38(6):1552-62
pubmed: 14647066